

# Jennifer G Goldman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7121/publications.pdf>

Version: 2024-02-01

77  
papers

12,149  
citations

87888

38  
h-index

85541

71  
g-index

79  
all docs

79  
docs citations

79  
times ranked

10275  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.1	2,805
2	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1689-1707.	3.9	2,497
3	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012, 27, 349-356.	3.9	1,908
4	MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD $\leq$ MCI. <i>Movement Disorders</i> , 2011, 26, 1814-1824.	3.9	649
5	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, 743-755.	1.1	365
6	Premotor and nonmotor features of Parkinson's disease. <i>Current Opinion in Neurology</i> , 2014, 27, 434-441.	3.6	253
7	$\hat{\pm}$ Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson $\hat{\text{e}}$ ™s disease. <i>Nature Communications</i> , 2020, 11, 1875.	12.8	239
8	Association of <i>GBA</i> Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 1217.	9.0	185
9	<i>GBA</i> Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 95-102.	3.9	158
10	A recommended scale for cognitive screening in clinical trials of Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2501-2507.	3.9	155
11	Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial. <i>Movement Disorders</i> , 2015, 30, 1657-1663.	3.9	143
12	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 208-218.	3.9	138
13	Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson $\hat{\text{e}}$ ™s disease with hallucinations. <i>Brain</i> , 2014, 137, 849-859.	7.6	135
14	Diagnosing PD $\leq$ MCI by MDS task force criteria: How many and which neuropsychological tests?. <i>Movement Disorders</i> , 2015, 30, 402-406.	3.9	125
15	Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. <i>Movement Disorders</i> , 2018, 33, 282-288.	3.9	122
16	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. <i>Movement Disorders</i> , 2017, 32, 1056-1065.	3.9	117
17	Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1972-1979.	3.9	110
18	Cognitive impairment in Parkinson $\hat{\text{e}}$ ™s disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. <i>Npj Parkinson's Disease</i> , 2018, 4, 19.	5.3	110

#	ARTICLE	IF	CITATIONS
19	The spectrum of cognitive impairment in Lewy body diseases. <i>Movement Disorders</i> , 2014, 29, 608-621.	3.9	107
20	Treatment of Psychosis and Dementia in Parkinson's Disease. <i>Current Treatment Options in Neurology</i> , 2014, 16, 281.	1.8	103
21	Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1129-1136.	3.9	87
22	α-synuclein genetic variability: A biomarker for dementia in Parkinson disease. <i>Annals of Neurology</i> , 2016, 79, 991-999.	5.3	85
23	Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. <i>Movement Disorders</i> , 2008, 23, 2248-2250.	3.9	81
24	Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease. <i>Neurology</i> , 2017, 88, 1265-1272.	1.1	71
25	Integrated Care in Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Movement Disorders</i> , 2020, 35, 1509-1531.	3.9	71
26	Functional Brain Activity Relates to 3 and 8 Hz Force Oscillations in Essential Tremor. <i>Cerebral Cortex</i> , 2015, 25, 4191-4202.	2.9	67
27	White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease. <i>Neurology</i> , 2018, 91, e2244-e2255.	1.1	66
28	Advances in the treatment of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1471-1489.	3.9	65
29	Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 806-811.	2.2	64
30	Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. <i>Neurobiology of Disease</i> , 2014, 69, 1-14.	4.4	56
31	Arguing against the proposed definition changes of PD. <i>Movement Disorders</i> , 2016, 31, 1619-1622.	3.9	55
32	Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018, 33, 503-510.	3.9	52
33	Genetic Polymorphisms in Parkinson Disease Subjects With and Without Hallucinations. <i>Archives of Neurology</i> , 2004, 61, 1280-4.	4.5	51
34	Clinical validation of movement disorder society's recommended diagnostic criteria for Parkinson's disease with dementia. <i>Movement Disorders</i> , 2012, 27, 248-253.	3.9	51
35	Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria. <i>Journal of Parkinson's Disease</i> , 2014, 4, 131-137.	2.8	50
36	Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. <i>Movement Disorders</i> , 2012, 27, 727-734.	3.9	49

#	ARTICLE	IF	CITATIONS
37	The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. <i>Movement Disorders</i> , 2016, 31, 924-932.	3.9	48
38	Cognitive Impairment and Dementia in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 365-377.	2.6	43
39	An update expert opinion on management and research strategies in Parkinson's disease psychosis. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2009-2024.	1.8	42
40	Detecting Mild Cognitive Deficits in Parkinson's Disease: A Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018, 33, 1750-1759.	3.9	42
41	Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1135-1139.	2.2	38
42	High-Spatial-Resolution Diffusion MRI in Parkinson Disease: Lateral Asymmetry of the Substantia Nigra. <i>Radiology</i> , 2019, 291, 149-157.	7.3	35
43	Risk of Parkinson's disease dementia related to level I MDS PD-MCI. <i>Movement Disorders</i> , 2019, 34, 430-435.	3.9	32
44	Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 137.	6.2	32
45	Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 11-22.	3.9	31
46	Treatment of Dystonia. <i>Clinical Neuropharmacology</i> , 2003, 26, 102-108.	0.7	29
47	Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2015, 5, 425-443.	2.2	28
48	Peripheral electrical stimulation to reduce pathological tremor: a review. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2021, 18, 33.	4.6	27
49	The Effects of Dual-Task Cognitive Interference and Environmental Challenges on Balance in Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 202-212.	1.5	24
50	Treatment of Nonmotor Symptoms Associated with Parkinson Disease. <i>Neurologic Clinics</i> , 2020, 38, 269-292.	1.8	21
51	Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 367-382.	6.1	21
52	Motor phenotype classification in moderate to advanced PD in BioFIND study. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 178-183.	2.2	20
53	Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures. <i>Npj Parkinson's Disease</i> , 2022, 8, 30.	5.3	20
54	Writer's cramp. <i>Toxicon</i> , 2015, 107, 98-104.	1.6	17

#	ARTICLE	IF	CITATIONS
55	Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials. <i>Movement Disorders</i> , 2018, 33, 528-536.	3.9	17
56	Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1760-1768.	3.9	17
57	Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. <i>Movement Disorders</i> , 2011, 26, 1781-1783.	3.9	15
58	Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable. <i>Journal of Parkinson's Disease</i> , 2014, 4, 585-589.	2.8	15
59	The effects of dual-task cognitive interference on gait and turning in Huntington's disease. <i>PLoS ONE</i> , 2020, 15, e0226827.	2.5	15
60	Clinical features of neurodegeneration with brain iron accumulation due to a <i>C19orf12</i> gene mutation. <i>Movement Disorders</i> , 2013, 28, 1462-1463.	3.9	14
61	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. <i>Frontiers in Neurology</i> , 2021, 12, 805135.	2.4	12
62	New Thoughts on Thought Disorders in Parkinson's Disease: Review of Current Research Strategies and Challenges. <i>Parkinson's Disease</i> , 2011, 2011, 1-12.	1.1	11
63	Level I MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 479-483.	1.5	11
64	Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 23.	6.2	9
65	Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. <i>Movement Disorders</i> , 2014, 29, 1252-1257.	3.9	7
66	Validation of an Online Screener, the Mediterranean Eating Pattern for Americans-III in Older Patients with Parkinson's Disease. <i>Journal of Nutrition in Gerontology and Geriatrics</i> , 2020, 39, 30-43.	1.0	3
67	Twelve Drummers Drumming   With Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2021, 11, 6.	2.0	3
68	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , 2018, 33, 499-500.	3.9	2
69	Reply To: Detection of alpha-synuclein in saliva: The importance of preanalytical assessment. <i>Movement Disorders</i> , 2018, 33, 1031-1031.	3.9	1
70	Shared imaging biomarkers across Alzheimer's and Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046542.	0.8	1
71	Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 124.	6.2	1
72	Acceptability and Reliability of an Online Version of the MEPA III Screener IN Parkinson's Participants (P01-010-19). <i>Current Developments in Nutrition</i> , 2019, 3, nzz028.P01-010-19.	0.3	0

#	ARTICLE	IF	CITATIONS
73	Creating a patient-centered guide to navigating cognitive change in Parkinson's disease. Alzheimer's and Dementia, 2020, 16, e041115.	0.8	0
74	The complexity of DLB: U.S.-based Dementia with Lewy Body Consortium. Alzheimer's and Dementia, 2020, 16, e042846.	0.8	0
75	Huntington disease. , 2021, , 371-400.e14.		0
76	Nonmotor problems in Parkinson disease. , 2021, , 234-248.e7.		0
77	Cognitive Syndromes Associated With Movement Disorders. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 726-749.	0.8	0